{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:37:42Z","timestamp":1757309862388,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002329","name":"Bundesamt f\u00fcr Gesundheit","doi-asserted-by":"publisher","award":["2020-00354"],"award-info":[{"award-number":["2020-00354"]}],"id":[{"id":"10.13039\/501100002329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Heroin-assisted treatment (HAT) is a proven effective treatment option for individuals with severe opioid use disorder (OUD). In Switzerland, pharmaceutical heroin (diacetylmorphine, DAM) is available in tablet form or as injectable liquid. This creates a large barrier for individuals who require the rapid onset of effect but are either unable or do not want to inject, or who primarily snort opioids. Early experimental data has demonstrated that intranasal DAM administration can be a viable alternative to the intravenous or intramuscular route of administration. The purpose of this study is to assess the feasibility, safety, and acceptability of intranasal HAT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study will assess intranasal DAM using a prospective multicentre observational cohort study design in HAT clinics across Switzerland. Patients will be offered to switch from oral or injectable DAM to intranasal DAM. Participants will be followed-up over 3\u00a0years, with assessments at baseline, and after 4, 52, 104 and 156\u00a0weeks. The primary outcome measure (POM) is retention in treatment. Secondary outcomes (SOM) include prescriptions and routes of administration of other opioid agonists, illicit substance use, risk behaviour, delinquency, health and social functioning, treatment adherence, opioid craving, satisfaction, subjective effects, quality of life, physical health, and mental health.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results derived from this study will generate the first major body of clinical evidence on the safety, acceptability, and feasibility of intranasal HAT. If proven to be safe, feasible and acceptable, this study would increase the accessibility of intranasal OAT for individuals with OUD globally as a critical improvement in risk reduction.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-023-00367-0","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:24:42Z","timestamp":1679862282000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Feasibility, safety, and acceptability of intranasal heroin-assisted treatment in Switzerland: protocol for a prospective multicentre observational cohort study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4720-8402","authenticated-orcid":false,"given":"Jean N.","family":"Westenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Krausz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth M.","family":"D\u00fcrsteler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Falcato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"issue":"1","key":"367_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/add.14442","volume":"114","author":"C Nordt","year":"2019","unstructured":"Nordt C, Vogel M, Dey M, Moldovanyi A, Beck T, Berthel T, et al. One size does not fit all\u2014evolution of opioid agonist treatments in a naturalistic setting over 23 years. Addiction. 2019;114(1):103\u201311.","journal-title":"Addiction"},{"issue":"1","key":"367_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1192\/bjp.bp.114.149195","volume":"207","author":"J Strang","year":"2015","unstructured":"Strang J, Groshkova T, Uchtenhagen A, van den Brink W, Haasen C, Schechter MT, et al. Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction. Br J Psychiatry. 2015;207(1):5\u201314.","journal-title":"Br J Psychiatry"},{"issue":"5","key":"367_CR3","first-page":"274","volume":"15","author":"J Strasser","year":"2013","unstructured":"Strasser J, Vogel M. Die Zukunft der heroingest\u00fctzten Behandlung aus klinischer Sicht in der Schweiz [The future of heroin assisted treatment from a clinical point of view]. Suchtmedizin Forschung Praxis. 2013;15(5):274\u20139.","journal-title":"Suchtmedizin Forschung Praxis"},{"issue":"5","key":"367_CR4","first-page":"267","volume":"19","author":"M Vogel","year":"2017","unstructured":"Vogel M, Strasser J. Alternativen in der Behandlung mit im Zentralnervensystem rasch anflutenden opioiden. Suchtmedizin. 2017;19(5):267\u201374.","journal-title":"Suchtmedizin"},{"issue":"1","key":"367_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1747-597X-6-9","volume":"6","author":"KM D\u00fcrsteler-MacFarland","year":"2011","unstructured":"D\u00fcrsteler-MacFarland KM, Vogel M, Wiesbeck GA, Petitjean SA. There is no age limit for methadone: a retrospective cohort study. Subst Abuse Treat Prev Policy. 2011;6(1):9.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"2","key":"367_CR6","first-page":"57","volume":"17","author":"M Vogel","year":"2015","unstructured":"Vogel M, D\u00fcrsteler K, Strasser J, Schmid O, M\u00fcller E, Himmelheber P, et al. Injektionen in die Leistenvene: Pr\u00e4valenz und Umgang in heroingest\u00fctzter Behandlung. Suchtmedizin. 2015;17(2):57\u201362.","journal-title":"Suchtmedizin"},{"key":"367_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drugalcdep.2016.11.029","volume":"171","author":"S Larney","year":"2017","unstructured":"Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of injecting-related injury and disease among people who inject drugs. Drug Alcohol Depend. 2017;171:39\u201349.","journal-title":"Drug Alcohol Depend"},{"key":"367_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.drugpo.2015.11.003","volume":"28","author":"VDD Hope","year":"2016","unstructured":"Hope VDD, Parry JVV, Ncube F, Hickman M. Not in the vein: \u2018missed hits\u2019, subcutaneous and intramuscular injections and associated harms among people who inject psychoactive drugs in Bristol, United Kingdom. Int J Drug Policy. 2016;28:83\u201390.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"367_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-021-00584-3","volume":"18","author":"M Meyer","year":"2021","unstructured":"Meyer M, Eichenberger R, Strasser J, D\u00fcrsteler KM, Vogel M. \u00abOne prick and then it\u00b4s done\u00bb: a mixed-methods exploratory study on intramuscular injection in heroin-assisted treatment. Harm Reduct J. 2021;18(1):1\u201310. https:\/\/doi.org\/10.1186\/s12954-021-00584-3.","journal-title":"Harm Reduct J."},{"issue":"4","key":"367_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0009-9236(03)00199-1","volume":"74","author":"F Girardin","year":"2003","unstructured":"Girardin F, Rentsch KM, Schwab MA, Maggiorini M, Pauli-Magnus C, Kullak-Ublick GA, et al. Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. Clin Pharmacol Ther. 2003;74(4):341\u201352.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"367_CR11","doi-asserted-by":"publisher","first-page":"486","DOI":"10.5414\/CPP38486","volume":"38","author":"E Gyr","year":"2000","unstructured":"Gyr E, Brenneisen R, Bourquin D, Lehmann T, Vonlanthen D, Hug I. Pharmacodynamics and pharmacokinetics of intravenously, orally and rectally administered diacetylmorphine in opioid dependents, a two-patient pilot study within a heroin-assisted treatment program. Int J Clin Pharmacol Ther. 2000;38(10):486\u201391.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"367_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.drugalcdep.2005.04.008","volume":"80","author":"MG Klous","year":"2005","unstructured":"Klous MG, Van den Brink W, Van RJM, Beijnen JH. Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients. Drug Alcohol Depend. 2005;80(3):283\u201395.","journal-title":"Drug Alcohol Depend"},{"key":"367_CR13","unstructured":"Gesundheitsdepartement Basel-Stadt. Bericht Kontakt- und Anlaufstellen Basel-Stadt 2016\u2014Statistische Auswertung der Besucherzahlen, Konsumh\u00e4ufigkeiten und konsumierten Substanzen. Basel. 2017."},{"key":"367_CR14","volume-title":"Luxembourg","author":"EMCDDA. European Drug Report","year":"2017","unstructured":"EMCDDA. European Drug Report. Luxembourg. Luxembourg: Publications Office of the European Union; 2017."},{"issue":"2","key":"367_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000090428","volume":"12","author":"TB Mitchell","year":"2006","unstructured":"Mitchell TB, Lintzeris N, Bond A, Strang J. Feasibility and acceptability of an intranasal diamorphine spray as an alternative to injectable diamorphine for maintenance treatment. Eur Addict Res. 2006;12(2):91\u20135.","journal-title":"Eur Addict Res"},{"issue":"1","key":"367_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1742-7843.2006.pto_233.x","volume":"98","author":"EJ Rook","year":"2006","unstructured":"Rook EJ, Van Ree JM, Van Den Brink W, Hillebrand MJX, Huitema ADR, Hendriks VM, et al. Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic Clin Pharmacol Toxicol. 2006;98(1):86\u201396.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"367_CR17","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s002130050956","volume":"143","author":"SD Comer","year":"1999","unstructured":"Comer SD, Collins ED, MacArthur RB, Fischman MW. Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans. Psychopharmacology. 1999;143(4):327\u201338.","journal-title":"Psychopharmacology"},{"issue":"3","key":"367_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.drugalcdep.2011.06.020","volume":"119","author":"DC Des Jarlais","year":"2011","unstructured":"Des Jarlais DC, Hagan H, Arasteh K, McKnight C, Semaan S, Perlman DC. Can intranasal drug use reduce HCV infection among injecting drug users? Drug Alcohol Depend. 2011;119(3):201\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"367_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12954-022-00644-2","volume":"19","author":"M Meyer","year":"2022","unstructured":"Meyer M, Westenberg JN, Strasser J, D\u00fcrsteler KM, Lang UE, Krausz M, et al. Nasal administration of diacetylmorphine improved the adherence in a patient receiving heroin-assisted treatment. Harm Reduct J. 2022;19(1):63.","journal-title":"Harm Reduct J"},{"issue":"1","key":"367_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000516431","volume":"28","author":"M Vogel","year":"2022","unstructured":"Vogel M, K\u00f6ck P, Strasser J, Kalbermatten C, Binder H, D\u00fcrsteler KM, et al. Nasal opioid agonist treatment in patients with severe opioid dependence: a case series. Eur Addict Res. 2022;28(1):80\u20136.","journal-title":"Eur Addict Res"},{"issue":"4","key":"367_CR21","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1046\/j.1360-0443.2000.9545698.x","volume":"95","author":"S Darke","year":"2000","unstructured":"Darke S, Ross J. Fatal heroin overdoses resulting from non-injecting routes of administration, NSW, Australia, 1992\u20131996. Addiction. 2000;95(4):569\u201373.","journal-title":"Addiction"},{"issue":"6","key":"367_CR22","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1046\/j.1365-2044.2000.01373.x","volume":"55","author":"A Hallett","year":"2000","unstructured":"Hallett A, O\u2019Higgins F, Francis V, Cook TM. Patient-controlled intranasal diamorphine for postoperative pain. Anaesthesia. 2000;55(6):532\u20139.","journal-title":"Anaesthesia"},{"issue":"1","key":"367_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1046\/j.1365-2044.2002.02263.x","volume":"57","author":"M Ward","year":"2002","unstructured":"Ward M, Minto G, Alexander-Williams JM. A comparison of patient-controlled analgesia administered by the intravenous or intranasal route during the early postoperative period. Anaesthesia. 2002;57(1):49\u201352.","journal-title":"Anaesthesia"},{"issue":"6","key":"367_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/jat\/17.6.327","volume":"17","author":"EJ Cone","year":"1993","unstructured":"Cone EJ, Holicky BA, Grant TM, Darwin WD, Goldberger BA. Pharmacokinetics and pharmacodynamics of intranasal \u201csnorted\u201d heroin. J Anal Toxicol. 1993;17(6):327\u201337.","journal-title":"J Anal Toxicol"},{"issue":"2","key":"367_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/jat\/21.2.105","volume":"21","author":"G Skopp","year":"1997","unstructured":"Skopp G, Ganssmann B, Cone EJ, Aderjan R, Skoppl G, Ganssmann B, et al. Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration. J Anal Toxicol. 1997;21(2):105\u201311.","journal-title":"J Anal Toxicol"},{"issue":"8","key":"367_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/00008877-199712000-00002","volume":"8","author":"SD Comer","year":"1997","unstructured":"Comer SD, Collins ED, Fischman MW. Choice between money and intranasal heroin in morphine-maintained humans. Behav Pharmacol. 1997;8(8):677\u201390.","journal-title":"Behav Pharmacol"},{"issue":"6","key":"367_CR27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2165\/00003088-200342060-00001","volume":"42","author":"JM Kendall","year":"2003","unstructured":"Kendall JM, Latter VS. Intranasal diamorphine as an alternative to intramuscular morphine: pharmacokinetic and pharmacodynamic aspects. Clin Pharmacokinet. 2003;42(6):501\u201313.","journal-title":"Clin Pharmacokinet"},{"issue":"269","key":"367_CR28","first-page":"73","volume":"32","author":"J Kendall","year":"2015","unstructured":"Kendall J, Maconochie I, Wong ICK, Howard R, DIASAFE study on behalf of the D. A novel multipatient intranasal diamorphine spray for use in acute pain in children: pharmacovigilance data from an observational study. Emerg Med J. 2015;32(269):73.","journal-title":"Emerg Med J."},{"key":"367_CR29","unstructured":"Federal Office of Public Health FOPH. Diacetylmorphine-assisted (heroin-assisted) treatment [Internet]. 2022 [cited 2023 Mar 9]. https:\/\/www.bag.admin.ch\/bag\/en\/home\/gesund-leben\/sucht-und-gesundheit\/suchtberatung-therapie\/substitutionsgestuetzte-behandlung.html."},{"key":"367_CR30","unstructured":"Gmel G, Labhart F, Maffli E. Heroingest\u00fctzte\/diacetylmorphingest\u00fctzte Behandlung in der Schweiz\u2014Resultate der Erhebung 2020 (Forschungsbericht Nr. 135). 2021."},{"issue":"1","key":"367_CR31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13643-021-01764-9","volume":"10","author":"J Klimas","year":"2021","unstructured":"Klimas J, Hamilton MA, Gorfinkel L, Adam A, Cullen W, Wood E. Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials. Syst Rev. 2021;10(1):216. https:\/\/doi.org\/10.1186\/s13643-021-01764-9.","journal-title":"Syst Rev."},{"issue":"9","key":"367_CR32","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","volume":"78","author":"T Santo Jr","year":"2021","unstructured":"Santo T Jr, Clark B, Hickman M, Grebely J, Campbell G, Sordo L, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979\u201393. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.0976.","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"367_CR33","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1111\/j.1360-0443.2008.02185.x","volume":"103","author":"U Verthein","year":"2008","unstructured":"Verthein U, Bonorden-Kleij K, Degkwitz P, Dilg C, K\u00f6hler WK, Passie T, et al. Long-term effects of heroin-assisted treatment in Germany. Addiction. 2008;103(6):960.","journal-title":"Addiction"},{"issue":"2","key":"367_CR34","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1360-0443.2009.02754.x","volume":"105","author":"P Blanken","year":"2010","unstructured":"Blanken P, Hendriks VM, van Ree JM, van den Brink W. Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction. 2010;105(2):300\u20138. https:\/\/doi.org\/10.1111\/j.1360-0443.2009.02754.x.","journal-title":"Addiction"},{"issue":"1","key":"367_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1465-3362.2009.00100.x","volume":"29","author":"E Oviedo-Joekes","year":"2010","unstructured":"Oviedo-Joekes E, March JC, Romero M, Perea-Milla E. The Andalusian trial on heroin-assisted treatment: A 2 year follow-up. Drug Alcohol Rev. 2010;29(1):75\u201380. https:\/\/doi.org\/10.1111\/j.1465-3362.2009.00100.x.","journal-title":"Drug Alcohol Rev"},{"key":"367_CR36","first-page":"2194","volume":"20","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. WMA declaration of Helsinki\u2014ethical principles for medical research involving human subjects\u2014WMA\u2014the world medical association. JAMA. 2013;20:2194.","journal-title":"JAMA."},{"issue":"1718","key":"367_CR37","first-page":"w14615","volume":"148","author":"The Swiss Federal Council","year":"2018","unstructured":"The Swiss Federal Council. Ordinance on human research with the exception of clinical trials (HRO). Swiss Med Week. 2018;148(1718):w14615\u2013w14615.","journal-title":"Swiss Med Week"},{"issue":"9","key":"367_CR38","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1111\/j.1360-0443.2008.02284.x","volume":"103","author":"J Marsden","year":"2008","unstructured":"Marsden J, Farrell M, Bradbury C, Dale-Perera A, Eastwood B, Roxburgh M, et al. Development of the treatment outcomes profile. Addiction. 2008;103(9):1450\u201360.","journal-title":"Addiction"},{"issue":"3","key":"367_CR39","first-page":"1002","volume":"243","author":"KL Preston","year":"1987","unstructured":"Preston KL, Bigelow GE, Bickel W, Liebson IA. Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline. J Pharmacol Exp Ther. 1987;243(3):1002.","journal-title":"J Pharmacol Exp Ther"},{"key":"367_CR40","volume-title":"The opiate treatment index manual technical report 11","author":"S Darke","year":"1991","unstructured":"Darke S, Ward J, Hall W, Heather N, Wodak A. The opiate treatment index manual technical report 11. Sydney: National Drug and Alcohol Research; 1991."},{"issue":"5","key":"367_CR41","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1055\/s-2003-814786","volume":"54","author":"J Hardt","year":"2004","unstructured":"Hardt J, Egle UT, Kappis B, Hessel A, Br\u00e4hler E. Die Symptom-Checkliste SCL-27. PPmP Psychotherapie Psychosomatik Medizinische Psychol. 2004;54(5):214\u201323.","journal-title":"PPmP Psychotherapie Psychosomatik Medizinische Psychol."},{"issue":"1","key":"367_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-023-00731-y","volume":"20","author":"M Vogel","year":"2023","unstructured":"Vogel M, Meyer M, Westenberg JN, Kormann A, Simon O, Salim R, et al. Safety and feasibility of intranasal heroin-assisted treatment: 4-week preliminary findings from a Swiss multicentre observational study. Harm Reduct J. 2023;20(1):1\u20138. https:\/\/doi.org\/10.1186\/s12954-023-00731-y.","journal-title":"Harm Reduct J"},{"issue":"2","key":"367_CR43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S2215-0366(21)00393-X","volume":"9","author":"RM Krausz","year":"2022","unstructured":"Krausz RM, Westenberg JN, Vogel M. Addressing fentanyl use disorder with fentanyl-assisted treatment. Lancet Psychiatry. 2022;9(2):103\u20135.","journal-title":"Lancet Psychiatry"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00367-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-023-00367-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00367-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:27:51Z","timestamp":1679862471000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-023-00367-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["367"],"URL":"https:\/\/doi.org\/10.1186\/s13722-023-00367-0","relation":{},"ISSN":["1940-0640"],"issn-type":[{"type":"electronic","value":"1940-0640"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"8 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol received ethical approval from the Ethikkommission Nordwest\u2014und. Zentralschweiz (EKNZ) [Northwest and Central Switzerland Ethics Committee] and all responsible ethics committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable: no personal identifier is included.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MV has received consultation and speaker fees from Camurus. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}